Page 96 - Genetic Engineering News Today

Reuters | Havana | Updated: 09-07-2021 05:41 IST | Created: 09-07-2021 05:41 IST Country: SHARE Cuba said on Thursday that its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala vaccine last month at 92.28% efficacy The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees the Finlay Institute, the maker of Sobe...

Транзисторные машины СССР Разработка первых советских германиевых плоскостных транзисторов началась через год после General Electric – в 1953 году, в серийное производство КСВ-1 и КСВ-2 пошли в 1955 году (позже, как обычно, все было многократно переименовано, и они получили индексы ...

2021-07-09 23:35:12 GMT2021-07-10 07:35:12(Beijing Time) Xinhua English HAVANA, July 9 (Xinhua) -- The Cuban Center for State Control of Medicines, Equipment and Medical Devices on Friday gave emergency use authorization to Abdala, one of five vaccines against COVID-19 being developed by Cuban scientists. The regulatory body said in a statement it granted emergency use authorization to Abdala "once it was confirmed that the requirements and parameters demanded in terms of quality, safety...

17 42 Dio a conocer el Ministerio de Salud Pública de Cuba que la vacuna Abdala recibió la autorización de uso de emergencia tras realizar la fase III de pruebas clínicas y entregar los resultados. La aprobación la otorgó la autoridad sanitaria del país: el Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED) de Cuba, después confirmar que cumple el fármaco con los requisitos de “calidad, seguridad y eficacia”. Abdala se convierte así en la p...

A Abdala, um dos cinco imunizantes desenvolvidos pelo país caribenho contra covid-19 e o primeiro a obter aprovação, é um imunógeno de subunidade com esquema de administração intramuscular de três doses em 28 dias e foi criado pelo estatal Centro de Engenharia Genética e Biotecnologia. Ao receber o sinal verde para seu uso emergencial, a Abdala passa de vacina candidata a ser oficialmente reconhecida como vacina, sendo a primeira do tipo a ser desenvolvida na América Latina. A nota da...

Cuba approves emergency use of homemade COVID-19 vaccine Xinhua | Updated: 2021-07-10 08:26 Share CLOSE A nurse applies a dose of Abdala vaccine against the coronavirus at a vaccination center in Havana, Cuba, June 23, 2021. REUTERS/Alexandre Meneghini HAVANA -- The Cuban Center for State Control of Medicines, Equipment and Medical Devices on Friday gave emergency use authorization to Abdala, one of five vaccines against COVID-19 being developed by ...

Просмотров: 1593 AstraZeneca и Sinovac CentralAsia (CA) -  Комбинация вакцин от британо-шведской компании AstraZeneca и китайской Sinovac позволяет защититься от дельта-варианта коронавируса (так называемого «индийского штамма»). К такому выводу пришли ученые из Таиланда, передает телеканал Thai PBS. �...

Cuba approves emergency use of domestic Covid vax   Sat, Jul 10 2021 09:32:48 AM Havana, Jul 10 (IANS): The Cuban Centre for State Control of Medicines, Equipment and Medical Devices has approved the emergency use authorisation to Abdala, one of five domestic vaccines against Covid-19. The regulatory body said in a statement on Friday that it granted the emergency use authorization to Abdala "once it was confirmed that the requirements and parameters demanded in terms of quality, safety and e...

Marc Frank 3 minute read A nurse prepares a dose of the Soberana 02 vaccine during its clinical trials at a hospital amid concerns about the spread of the coronavirus disease (COVID-19) in Havana, Cuba, June 29, 2021. REUTERS/Alexandre Meneghini HAVANA, July 8 (Reuters) - Cuba said on Thursday its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala va...

By Reuters Staff 1 Min Read HAVANA, July 8 (Reuters) - Cuba said on Thursday that its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala vaccine last month at 92.28% efficacy The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees the Finlay Institute, the maker of Soberana 2, and the Center for Genetic Enginee...